Kling doses first subject in Phase Ib solid tumour antibody trial

Kling doses first subject in Phase Ib solid tumour antibody trial

Source: 
Clinical Trials Arena
snippet: 

Kling Biotherapeutics has dosed the first subject in its Phase Ib KBA1412-101 clinical trial of antibody KBA1412 in adults with advanced solid tumours unresponsive to standard of care.